Categories AlphaGraphs, Earnings, Health Care
Eli Lilly (LLY) Q3 2024 Earnings: Key financials and quarterly highlights
Eli Lilly and Company (NYSE: LLY) reported its third quarter 2024 earnings results today.
Worldwide revenue was $11.44 billion, up 20% compared to the same period a year ago.
GAAP net income was $970.3 million, or $1.07 per share, compared to a net loss of $57.4 million, or $0.06 per share, last year. Adjusted EPS was $1.18.
Revenue and earnings missed expectations, sending the stock plunging over 13% on Wednesday.
For fiscal year 2024, the company expects revenues of $45.4-46.0 billion, GAAP EPS of $12.05-12.55 and adjusted EPS of $13.02-13.52.
Prior performance
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
Key takeaways from JM Smucker’s (SJM) Q4 2025 earnings report
Shares of The J.M. Smucker Co. (NYSE: SJM) plunged 15% on Tuesday after the company delivered mixed results for the fourth quarter of 2025. While earnings came ahead of expectations,
J.M. Smucker (SJM) Q4 2025 Earnings: Key financials and quarterly highlights
The J.M. Smucker Co. (NYSE: SJM) reported its fourth quarter 2025 earnings results today. Net sales was $2.1 billion, down 3% year-over-year. Comparable net sales decreased 1%. Net loss was
Plus Therapeutics CEO: Lead candidate REYOBIQ demonstrates strong safety and efficacy in early trials
Plus Therapeutics (NASDAQ: PSTV) is a pharmaceutical company engaged in the development of targeted radiotherapeutics for difficult-to-treat cancers. Currently, it is advancing a pipeline of product candidates with lead programs
